Submit Manuscript  

Article Details


Major Highlights of the CAR-TCR Summit, Boston, 2016

[ Vol. 17 , Issue. 10 ]

Author(s):

Vita Golubovskaya, Robert Berahovich, Shirley Xu, Hizkia Harto and Lijun Wu   Pages 1344 - 1350 ( 7 )

Abstract:


Cellular immunotherapies such as CAR-T cell therapy and TCR-T cell therapy are relatively new, highly promising approaches for the treatment of cancer. In CAR-T cell therapy, a patient's T cells are engineered to express chimeric antigen receptors targeting tumor-associated cell surface antigens. In TCR-T cell therapy, the patient's T cells are engineered to express receptors targeting intracellular antigens. This report will summarize presentations from the recent CAR-TCR summit in Boston on September 13-16, 2016. These presentations were given by leaders in the field and many were divided into three streams: Discovery and Genetic T Cell Engineering; Translation and Clinical Development; and Manufacturing, Supply Chain and Commercialization. The report summarizes major pharmaceutical companies developing these novel therapies and provides challenges and perspectives for future therapeutic developments.

Keywords:

Chimeric antigen receptor, immunotherapy, cytokine, cancer, tumor antigen, T-cell enginering.

Affiliation:

Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806, Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806, Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806, Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806, Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806

Graphical Abstract:



Read Full-Text article